Drug Profile
Tralokinumab - LEO Pharma
Alternative Names: Adbry; Adtralza; CAT-354; LP 0162Latest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator Cambridge Antibody Technology
- Developer Karolinska University Hospital; LEO Pharma; MedImmune
- Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atopic dermatitis
- Phase II Alopecia areata
- Discontinued Asthma; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Ulcerative colitis
Most Recent Events
- 19 Mar 2024 Launched for Atopic dermatitis (Combination therapy, Treatment-experienced) in USA (SC)
- 15 Mar 2024 LEO Pharma plans a phase III TRAPEDS 2 trial for Atopic dermatitis (Combination therapy, In infants, In children) (SC) in May 2024 (NCT06311682)
- 15 Dec 2023 Launched for Atopic dermatitis (In adolescents, Monotherapy) in USA (SC)